Context Therapeutics Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 233.5K | $611.79K | 0.00% | Added+41.0% | 2026-03-31 |
| RenTech | quant | 183.0K | $479.46K | 0.00% | Trimmed-64.0% | 2026-03-31 |
| Citadel | multi-strat | 57.2K | $149.94K | 0.00% | Added+8.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-06 | -0.12 | -0.09 | +23.40% |
| 2026-03-23 | -0.11 | -0.14 | -32.63% |
| 2025-11-05 | -0.09 | -0.10 | -14.29% |
| 2025-08-06 | -0.06 | -0.09 | -44.00% |
| 2025-05-07 | -0.06 | -0.05 | +21.05% |
| 2025-03-20 | -0.09 | — | +100.00% |
| 2024-11-06 | -0.09 | -0.22 | -144.44% |
| 2024-08-07 | -0.07 | -0.04 | +40.00% |
| 2024-05-08 | -0.44 | -0.23 | +47.73% |
| 2024-03-21 | -0.35 | -0.42 | -20.00% |
| 2023-11-09 | -0.31 | -0.37 | -19.35% |
| 2023-08-09 | -0.20 | -0.31 | -55.00% |
| 2023-05-10 | -0.19 | -0.40 | -110.53% |
| 2023-03-22 | -0.29 | -0.22 | +25.42% |
| 2022-11-09 | -0.25 | -0.24 | +4.00% |
| 2022-08-11 | -0.25 | -0.25 | — |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CNTX | +25.55% | +19.75% | +93.88% | +393.93% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +22.58% | +24.39% | +97.32% | +381.25% |